Thrombotic Thrombocytopenic Purpura and Related Thrombotic Microangiopathies

[1]  M. Scully,et al.  Ofatumumab for TTP in a Patient with Anaphylaxis Associated with Rituximab. , 2018, The New England journal of medicine.

[2]  D. Garcia,et al.  External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment , 2018, Journal of thrombosis and haemostasis : JTH.

[3]  Daniel Li,et al.  Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. , 2017, Blood.

[4]  G. Koretzky,et al.  Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era , 2017, Arthritis & rheumatology.

[5]  A. Ishiguro,et al.  Acquired idiopathic thrombotic thrombocytopenic purpura successfully treated with intravenous immunoglobulin and glucocorticoid , 2017, Medicine.

[6]  Ang Li,et al.  Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. , 2017, The Lancet. Haematology.

[7]  M. Cottler-Fox,et al.  Acquired Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome Successfully Treated with Eculizumab , 2017, Proceedings.

[8]  Evelena P. Ontiveros,et al.  Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib , 2017, Case reports in hematology.

[9]  H. Deckmyn,et al.  N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura. , 2017, Blood.

[10]  P. Buehler,et al.  A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER. , 2017, Blood.

[11]  J. George,et al.  Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer. , 2016, Journal of oncology practice.

[12]  Andrea Popescu-Martinez,et al.  N-Acetylcysteine for Relapsing Thrombotic Thrombocytopenic Purpura: More Evidence of a Promising Drug. , 2016, American journal of therapeutics.

[13]  Y. Pers,et al.  Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases. , 2016, Immunotherapy.

[14]  S. Hurwitz,et al.  Treatment with or without plasma exchange for patients with acquired thrombotic microangiopathy not associated with severe ADAMTS13 deficiency: a propensity score–matched study , 2016, Transfusion.

[15]  D. Cines,et al.  Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a potential link of inflammation to TTP. , 2016, Blood.

[16]  W. Clark,et al.  Treatment of severe, refractory and rapidly evolving thrombotic thrombocytopenic purpura , 2016, BMJ Case Reports.

[17]  Tina Dutt,et al.  Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura , 2016, British journal of haematology.

[18]  A. Rottenstreich,et al.  The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura , 2016, Journal of Thrombosis and Thrombolysis.

[19]  E. Ostertag,et al.  ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro , 2016, Transfusion.

[20]  B. Jilma,et al.  Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. , 2016, The New England journal of medicine.

[21]  Junmei Chen,et al.  High-density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion. , 2016, Blood.

[22]  E. Wang,et al.  Rituximab‐refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib , 2016, Transfusion.

[23]  G. Remuzzi,et al.  Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  T. Springer,et al.  Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTS‐13 , 2015, Journal of thrombosis and haemostasis : JTH.

[25]  A. Heath,et al.  Establishment of the WHO 1st International Standard ADAMTS13, plasma (12/252): communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.

[26]  D. Ginsburg,et al.  Probing ADAMTS13 Substrate Specificity using Phage Display , 2015, PloS one.

[27]  D. Bolger,et al.  Thrombotic thrombocytopenic purpura as an initial presentation of systemic lupus erythematosus with acquired ADAMTS 13 antibody , 2015, BMJ Case Reports.

[28]  N. Tolia,et al.  Allosteric activation of ADAMTS13 by von Willebrand factor , 2014, Proceedings of the National Academy of Sciences.

[29]  D. Lane,et al.  Conformational activation of ADAMTS13 , 2014, Proceedings of the National Academy of Sciences.

[30]  Junmei Chen,et al.  Hypochlorous Acid Generated by Neutrophils Inactivates ADAMTS13 , 2014, The Journal of Biological Chemistry.

[31]  E. Wood,et al.  N‐Acetylcysteine for thrombotic thrombocytopenic purpura: is a von Willebrand factor–inhibitory dose feasible in vivo? , 2014, Transfusion.

[32]  R. Sarode,et al.  Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report , 2014, Transfusion.

[33]  J. Moake,et al.  Treatment of refractory thrombotic thrombocytopenic purpura with N‐acetylcysteine: a case report , 2014, Transfusion.

[34]  J. Raval,et al.  Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura , 2014, British journal of haematology.

[35]  M. Schreuder,et al.  Refractory thrombotic thrombocytopenic purpura in a 16‐year‐old girl: successful treatment with bortezomib , 2014, European journal of haematology.

[36]  J. Laurence,et al.  Use of eculizumab in the treatment of a case of refractory, ADAMTS13‐deficient thrombotic thrombocytopenic purpura: additional data and clinical follow‐up , 2013, British journal of haematology.

[37]  K. Friedman,et al.  An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura , 2013, Journal of thrombosis and haemostasis : JTH.

[38]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[39]  D. Kirschke,et al.  Thrombotic Thrombocytopenic Purpura (TTP)–Like Illness Associated with Intravenous Opana ER Abuse — Tennessee, 2012 , 2013, MMWR. Morbidity and mortality weekly report.

[40]  S. Opat,et al.  ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. , 2013, The New England journal of medicine.

[41]  V. Frémeaux-Bacchi,et al.  Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies , 2012, Nature Reviews Nephrology.

[42]  Junmei Chen,et al.  Simultaneous Exposure of Sites in von Willebrand Factor for Glycoprotein Ib Binding and ADAMTS13 Cleavage: Studies With Ristocetin , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[43]  Jing-fei Dong,et al.  Thrombotic thrombocytopenic purpura and anti-thrombotic therapy targeted to von Willebrand factor. , 2012, Current vascular pharmacology.

[44]  J. Holz,et al.  Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. , 2012, Blood.

[45]  R. Liesner,et al.  A phenotype–genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom , 2012, Journal of thrombosis and haemostasis : JTH.

[46]  É. Azoulay,et al.  Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. , 2012, Blood.

[47]  C. Gerloff,et al.  The neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak. , 2012, Brain : a journal of neurology.

[48]  B. Weksler,et al.  Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura , 2012, British journal of haematology.

[49]  V. Vaillant,et al.  Outbreak of Shiga toxin-producing Escherichia coli O104:H4 associated with organic fenugreek sprouts, France, June 2011. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  Ying Zheng,et al.  In vitro microvessels for the study of angiogenesis and thrombosis , 2012, Proceedings of the National Academy of Sciences.

[51]  N. Tun,et al.  Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis , 2012, Journal of Thrombosis and Thrombolysis.

[52]  J. George.  Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura , 2012, American journal of hematology.

[53]  H. Kwaan,et al.  Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. , 2012, Blood.

[54]  L. Beutin,et al.  Outbreak of Shiga toxin-producing Escherichia coli (STEC) O104:H4 infection in Germany causes a paradigm shift with regard to human pathogenicity of STEC strains. , 2012, Journal of food protection.

[55]  Klaus Stark,et al.  Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. , 2011, The New England journal of medicine.

[56]  Matthias Greiner,et al.  German outbreak of Escherichia coli O104:H4 associated with sprouts. , 2011, The New England journal of medicine.

[57]  S. Vesely,et al.  Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency , 2011, Transfusion.

[58]  D. Lane,et al.  Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. , 2011, Blood.

[59]  A. Mellmann,et al.  Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. , 2011, The Lancet. Infectious diseases.

[60]  Junhua Li,et al.  Open-source genomic analysis of Shiga-toxin-producing E. coli O104:H4. , 2011, The New England journal of medicine.

[61]  J. Cavenagh,et al.  A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. , 2011, Blood.

[62]  B. Jilma,et al.  A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombo - cytopenic purpura , 2011, Thrombosis and Haemostasis.

[63]  P. Stanssens,et al.  Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. , 2011, Blood.

[64]  Salvatore Rubino,et al.  Escherichia coli (STEC) serotype O104 outbreak causing haemolytic syndrome (HUS) in Germany and France. , 2011, Journal of infection in developing countries.

[65]  Juan Xiao,et al.  A shear‐based assay for assessing plasma ADAMTS13 activity and inhibitors in patients with thrombotic thrombocytopenic purpura , 2011, Transfusion.

[66]  S Morabito,et al.  Characteristics of the enteroaggregative Shiga toxin/verotoxin-producing Escherichia coli O104:H4 strain causing the outbreak of haemolytic uraemic syndrome in Germany, May to June 2011. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[67]  J. Moake,et al.  N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. , 2011, The Journal of clinical investigation.

[68]  B. Jilma,et al.  Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura , 2010, Thrombosis and Haemostasis.

[69]  K. McCrae.  Thrombocytopenia in pregnancy. , 2010, Hematology. American Society of Hematology. Education Program.

[70]  Junmei Chen,et al.  Shear stress-induced unfolding of VWF accelerates oxidation of key methionine residues in the A1A2A3 region. , 2010, Blood.

[71]  J. George,et al.  How I treat patients with thrombotic thrombocytopenic purpura: 2010. , 2010, Blood.

[72]  S. Neelamegham,et al.  von Willebrand factor self-association on platelet GpIbalpha under hydrodynamic shear: effect on shear-induced platelet activation. , 2010, Blood.

[73]  S. Vesely,et al.  Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic‐uremic syndromes , 2010, American journal of hematology.

[74]  D. Lane,et al.  The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity. , 2010, Blood.

[75]  F. Liu,et al.  Thrombospondin-1 and ADAMTS13 competitively bind to VWF A2 and A3 domains in vitro. , 2010, Thrombosis research.

[76]  M. Papi,et al.  Ristocetin-induced self-aggregation of von Willebrand factor , 2010, European Biophysics Journal.

[77]  Y. Ubara,et al.  Etanercept-refractory adult-onset Still’s disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab , 2010, Clinical Rheumatology.

[78]  R. Claus,et al.  The balance between von-Willebrand factor and its cleaving protease ADAMTS13: biomarker in systemic inflammation and development of organ failure? , 2010, Current molecular medicine.

[79]  J. Voorberg,et al.  An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. , 2010, Blood.

[80]  S. Vesely,et al.  Survival and relapse in patients with thrombotic thrombocytopenic purpura. , 2010, Blood.

[81]  Junmei Chen,et al.  Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. , 2010, Blood.

[82]  J. Kiss.  Thrombotic thrombocytopenic purpura: recognition and management , 2010, International journal of hematology.

[83]  B. Jilma,et al.  Anti–von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura , 2009, Transfusion.

[84]  S. Ferrari,et al.  IgG subclass distribution of anti‐ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura , 2009, Journal of thrombosis and haemostasis : JTH.

[85]  D. Lane,et al.  Essential role of the disintegrin-like domain in ADAMTS13 function. , 2009, Blood.

[86]  José A López,et al.  Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: A mechanism associated with sickle cell disease , 2009, Thrombosis and Haemostasis.

[87]  S. Vesely,et al.  Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura , 2009, Transfusion.

[88]  J. McEwan,et al.  Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13 , 2009, Journal of thrombosis and haemostasis : JTH.

[89]  J. Voorberg,et al.  VH1‐69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura , 2009, Journal of thrombosis and haemostasis : JTH.

[90]  J. George,et al.  Pregnancy‐induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw–Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients , 2009, British journal of haematology.

[91]  Robyn Roth,et al.  Integrin alpha(v)beta(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress. , 2009, Blood.

[92]  J. Byrnes,et al.  Recent Therapeutic Advances in Thrombotic Thrombocytopenic Purpura , 2008, Seminars in thrombosis and hemostasis.

[93]  B. Lämmle,et al.  Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS‐13) , 2008, Journal of thrombosis and haemostasis : JTH.

[94]  Ian Mackie,et al.  Regional UK TTP Registry: correlation with laboratory ADAMTS 13 analysis and clinical features , 2008, British journal of haematology.

[95]  J. Moake,et al.  Covalent regulation of ULVWF string formation and elongation on endothelial cells under flow conditions , 2008, Journal of thrombosis and haemostasis : JTH.

[96]  Shili Lin,et al.  Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse , 2008, British journal of haematology.

[97]  S. Vesely,et al.  Sporadic bloody diarrhoea‐associated thrombotic thrombocytopenic purpura‐haemolytic uraemic syndrome: an adult and paediatric comparison , 2008, British journal of haematology.

[98]  A. Bertomoro,et al.  A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. , 2008, Blood.

[99]  F. Fabris,et al.  ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission , 2008, Haematologica.

[100]  H. Yoshiji,et al.  Plasma ADAMTS13 activity parallels the APACHE II score, reflecting an early prognostic indicator for patients with severe acute pancreatitis , 2008, Scandinavian journal of gastroenterology.

[101]  K. Reinhart,et al.  Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor , 2008, Haematologica.

[102]  J. M. Healy,et al.  First-in-Human Evaluation of Anti–von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy Volunteers , 2007, Circulation.

[103]  B. Lämmle,et al.  ADAMTS‐13, von Willebrand factor and related parameters in severe sepsis and septic shock , 2007, Journal of thrombosis and haemostasis : JTH.

[104]  M. Barry,et al.  Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. , 2007, Human gene therapy.

[105]  L. Trinquart,et al.  Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure* , 2007, Critical care medicine.

[106]  S. Karumanchi,et al.  Pre-Eclampsia: Clinical Manifestations and Molecular Mechanisms , 2007, Nephron Clinical Practice.

[107]  A Alexander-Katz,et al.  Shear-induced unfolding triggers adhesion of von Willebrand factor fibers , 2007, Proceedings of the National Academy of Sciences.

[108]  É. Oksenhendler,et al.  Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. , 2007, Blood.

[109]  Matthias F. Schneider,et al.  Soluble plasma-derived von Willebrand factor assembles to a haemostatically active filamentous network , 2007, Thrombosis and Haemostasis.

[110]  B. Dörken,et al.  Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. , 2007, Human immunology.

[111]  G. Basso,et al.  Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma , 2007, Leukemia.

[112]  P. Legendre,et al.  Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS‐13 , 2007, Journal of thrombosis and haemostasis : JTH.

[113]  J. Sadler,et al.  Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease , 2006, Proceedings of the National Academy of Sciences.

[114]  K. Fujikawa,et al.  Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor , 2006, Proceedings of the National Academy of Sciences.

[115]  T. Matsuyama,et al.  Novel monoclonal antibody‐based enzyme immunoassay for determining plasma levels of ADAMTS13 activity , 2006, Transfusion.

[116]  R. Schneppenheim,et al.  Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. , 2006, Blood.

[117]  J. Vermylen,et al.  Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13. , 2006, Blood.

[118]  T. Ohmori,et al.  Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. , 2006, Blood.

[119]  G. Remuzzi,et al.  Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA) , 2006, Thrombosis and Haemostasis.

[120]  K. Fujikawa,et al.  A rapid enzyme‐linked assay for ADAMTS‐13 , 2006, Journal of thrombosis and haemostasis : JTH.

[121]  J. Moake,et al.  Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. , 2005, Blood.

[122]  J. Moake,et al.  Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions. , 2005, Blood.

[123]  E. Bouhassira,et al.  Enzymatically Active ADAMTS13 Variants Are Not Inhibited by Anti-ADAMTS13 Autoantibodies , 2005, Journal of Biological Chemistry.

[124]  J. V. van Mourik,et al.  Amino acid regions 572–579 and 657–666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP , 2005, Thrombosis and Haemostasis.

[125]  M. Laffan,et al.  Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. , 2005, Blood.

[126]  Ping Zhang,et al.  The Proximal Carboxyl-terminal Domains of ADAMTS13 Determine Substrate Specificity and Are All Required for Cleavage of von Willebrand Factor* , 2005, Journal of Biological Chemistry.

[127]  Toshio Mori,et al.  Localization of ADAMTS13 to the stellate cells of human liver. , 2005, Blood.

[128]  Sanjeev Gupta,et al.  ADAMTS13 is expressed in hepatic stellate cells , 2005, Laboratory Investigation.

[129]  Yoshihiro Kokubo,et al.  FRETS‐VWF73, a first fluorogenic substrate for ADAMTS13 assay , 2005, British journal of haematology.

[130]  J. Cook,et al.  Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura , 2005, Annals of Hematology.

[131]  J. Moake,et al.  Platelets adhered to endothelial cell‐bound ultra‐large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress , 2005, Journal of thrombosis and haemostasis : JTH.

[132]  J. Kujovich,et al.  von Willebrand disease and pregnancy , 2005, Journal of thrombosis and haemostasis : JTH.

[133]  B. Jilma,et al.  Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation , 2005, Thrombosis and Haemostasis.

[134]  J. V. van Mourik,et al.  The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura , 2005, Thrombosis and Haemostasis.

[135]  J. Moake,et al.  Correlation of ADAMTS-13 Activity with Response to Plasma Exchange in Patients Diagnosed with Thrombotic Thrombocytopenic Purpura. , 2004 .

[136]  Jeffrey W. Clark,et al.  Gemcitabine‐associated thrombotic microangiopathy , 2004, Cancer.

[137]  B. Lämmle,et al.  Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. , 2004, Blood.

[138]  B. Lämmle,et al.  Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins. , 2004, Blood.

[139]  W. Fridman,et al.  Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome , 2004, Journal of Medical Genetics.

[140]  L. Goodnough,et al.  Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. , 2004, Blood.

[141]  J. Moake,et al.  P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. , 2004, Blood.

[142]  L. Hansson,et al.  Reference intervals for plasma levels of fibronectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy , 2004, Scandinavian journal of clinical and laboratory investigation.

[143]  M. Karmali.  Infection by shiga toxin-producing Escherichia coli , 2004, Molecular biotechnology.

[144]  I. Mackie,et al.  Comparison of von Willebrand factor antigen, von Willebrand factor‐cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura , 2004, Transfusion medicine.

[145]  S. Vesely,et al.  Severe deficiency of VWF‐cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients , 2004, Transfusion.

[146]  T. Miyata,et al.  VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. , 2004, Blood.

[147]  J. Pimanda,et al.  Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13. , 2004, Blood.

[148]  J. Sadler,et al.  Cleavage of the ADAMTS13 Propeptide Is Not Required for Protease Activity* , 2003, Journal of Biological Chemistry.

[149]  V. Pichette,et al.  Complement dysregulation in haemolytic uraemic syndrome , 2003, The Lancet.

[150]  L. Venat-Bouvet,et al.  Thrombotic microangiopathy and digital necrosis: two unrecognized toxicities of gemcitabine , 2003, Anti-cancer drugs.

[151]  M. Lazzari,et al.  Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[152]  D. Roth,et al.  Hemolytic uremic syndrome after multivisceral transplantation treated with intravenous immunoglobulin. , 2003, Journal of nephrology.

[153]  J. George.  The association of pregnancy with thrombotic thrombocytopenic purpura–hemolytic uremic syndrome , 2003, Current opinion in hematology.

[154]  J. Moake,et al.  ADAMTS-13 Metalloprotease Interacts with the Endothelial Cell-derived Ultra-large von Willebrand Factor* , 2003, Journal of Biological Chemistry.

[155]  C. Ponticelli,et al.  Successful treatment of hemolytic uremic syndrome after liver-kidney transplantation. , 2003, Journal of nephrology.

[156]  S. Vesely,et al.  ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. , 2003, Blood.

[157]  H. Shankaran,et al.  Aspects of hydrodynamic shear regulating shear-induced platelet activation and self-association of von Willebrand factor in suspension. , 2003, Blood.

[158]  A. Dispenzieri,et al.  Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. , 2003, Mayo Clinic proceedings.

[159]  E. Haddad,et al.  Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome. , 2003, The Journal of pediatrics.

[160]  H. Tsai,et al.  Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura , 2003, European journal of haematology.

[161]  L. Goodnough,et al.  Remission of Chronic Thrombotic Thrombocytopenic Purpura after Treatment with Cyclophosphamide and Rituximab , 2003, Annals of Internal Medicine.

[162]  Kazuo Fujikawa,et al.  ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. , 2002, Blood.

[163]  V. Diehl,et al.  Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab , 2002, American journal of hematology.

[164]  K. Fujikawa,et al.  Processing of von Willebrand factor by ADAMTS-13. , 2002, Biochemistry.

[165]  B. Lämmle,et al.  Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. , 2002, Blood.

[166]  Bahman Anvari,et al.  Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. , 2002, Blood.

[167]  L. Gutterman,et al.  Rituximab therapy for refractory thrombotic thrombocytopenic purpura. , 2002, Blood cells, molecules & diseases.

[168]  E. Gabazza,et al.  Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF‐cleaving protease activity , 2002, Transfusion.

[169]  J. Sixma,et al.  Functional self-association of von Willebrand factor during platelet adhesion under flow , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[170]  S. Vesely,et al.  Quinine-Associated Thrombotic Thrombocytopenic PurpuraHemolytic Uremic Syndrome: Frequency, Clinical Features, and Long-Term Outcomes , 2001, Annals of Internal Medicine.

[171]  K. Fujikawa,et al.  Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura* , 2001, The Journal of Biological Chemistry.

[172]  P. Mannucci,et al.  Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. , 2001, Blood.

[173]  T. Foroud,et al.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura , 2001, Nature.

[174]  Kazuo Fujikawa,et al.  Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. , 2001, Blood.

[175]  A. Houllier,et al.  Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. , 2001, Blood.

[176]  B. Lämmle,et al.  Ten years of prophylactic treatment with fresh‐frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor‐cleaving protease , 2001, British journal of haematology.

[177]  Craig S. Wong,et al.  Von Willebrand Factor and Von Willebrand Factor-Cleaving Metalloprotease Activity in Escherichia coli O157:H7-Associated Hemolytic Uremic Syndrome , 2001, Pediatric Research.

[178]  R. Liesner,et al.  von Willebrand factor‐cleaving protease activity in congenital thrombotic thrombocytopenic purpura , 2000, British journal of haematology.

[179]  H. Tsai.  High titers of inhibitors of von Willebrand factor‐cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura , 2000, American journal of hematology.

[180]  Z. Ruggeri.  Developing Basic and Clinical Research on von Willebrand Factor and von Willebrand Disease , 2000, Thrombosis and Haemostasis.

[181]  W R Bell,et al.  Thrombotic thrombocytopenic purpura associated with clopidogrel. , 2000, The New England journal of medicine.

[182]  R. Sarode,et al.  Antibody Inhibitors to von Willebrand Factor Metalloproteinase and Increased Binding of von Willebrand Factor to Platelets in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura , 2000, Annals of Internal Medicine.

[183]  B. Lämmle,et al.  Assay of von Willebrand Factor (vWF)-cleaving Protease Based on Decreased Collagen Binding Affinity of Degraded vWF , 1999, Thrombosis and Haemostasis.

[184]  J. Sixma,et al.  von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. , 1999, Blood.

[185]  L. Oleksowicz,et al.  Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies. , 1999, Cancer research.

[186]  B. Lämmle,et al.  von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. , 1998, The New England journal of medicine.

[187]  H. Tsai,et al.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. , 1998, The New England journal of medicine.

[188]  B. Lämmle,et al.  Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. , 1998, Blood.

[189]  J. Goodship,et al.  Genetic studies into inherited and sporadic hemolytic uremic syndrome. , 1998, Kidney international.

[190]  P. Yarnold,et al.  Thrombotic Thrombocytopenic Purpura Associated with Ticlopidine: A Review of 60 Cases , 1998, Annals of Internal Medicine.

[191]  B. Lämmle,et al.  Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. , 1997, Blood.

[192]  N. Heddle,et al.  Splenectomy Done during Hematologic Remission To Prevent Relapse in Patients with Thrombotic Thrombocytopenic Purpura , 1996, Annals of Internal Medicine.

[193]  K. Samii,et al.  Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy , 1996, American journal of hematology.

[194]  H. Tsai.  Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. , 1996, Blood.

[195]  B. Lämmle,et al.  Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. , 1996, Blood.

[196]  J. Moake,et al.  Thrombotic microangiopathies associated with drugs and bone marrow transplantation. , 1996, Hematology/oncology clinics of North America.

[197]  Nina Singh,et al.  Hemolytic uremic syndrome in solid‐organ transplant recipients , 1996 .

[198]  Y. Niihara,et al.  Concurrent thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in an HIV‐positive patient: Case report and review of the literature , 1996, American journal of hematology.

[199]  C. Wollheim,et al.  Reactive oxygen intermediates induce regulated secretion of von Willebrand factor from cultured human vascular endothelial cells. , 1995, Blood.

[200]  K. Titani,et al.  ABO Blood Group Genotype and Plasma von Willebrand Factor in Normal Individuals , 1995, Vox sanguinis.

[201]  T. Moore,et al.  Thrombotic microangiopathic hemolytic anemia in systemic lupus erythematosus , 1994 .

[202]  B. Djulbegovic,et al.  HLA‐DR53 protects against thrombotic thrombocytopenic purpura/adult hemolytic uremic syndrome , 1994, American journal of hematology/oncology.

[203]  J. Moake,et al.  Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. , 1994, Blood.

[204]  R. Nagel,et al.  Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. , 1994, Blood.

[205]  J. Moake.  Haemolytic-uraemic syndrome: basic science , 1994, The Lancet.

[206]  G. Zauli,et al.  Increased serum levels of transforming growth factor β‐1 in patients affected by thrombotic thrombocytopenic purpura (TTP): its implications on bone marrow haematopoiesis , 1993, British Journal of Haematology.

[207]  P. Bork,et al.  The CUB domain. A widespread module in developmentally regulated proteins. , 1993, Journal of molecular biology.

[208]  J. Moake,et al.  Abnormalities of von willebrand factor multimers in drug‐associated thrombotic microangiopathies , 1993, American journal of hematology.

[209]  L. Damon,et al.  Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. , 1992, Blood.

[210]  H. Wada,et al.  Plasma cytokine levels in thrombotic thrombocytopenic purpura , 1992, American journal of hematology.

[211]  J. Bennett,et al.  Disorders of platelet function: evaluation and treatment. , 1991, Cleveland Clinic journal of medicine.

[212]  W. Bell,et al.  Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. , 1991, The New England journal of medicine.

[213]  J. Kelton,et al.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. , 1991, The New England journal of medicine.

[214]  R. Aster,et al.  Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: a new clinical entity. , 1991, Blood.

[215]  J. Moake,et al.  Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura , 1990, American journal of hematology.

[216]  J. M. Martin,et al.  Thrombotic thrombocytopenic purpura causing sudden, unexpected death--a series of eight patients. , 1990, Journal of forensic sciences.

[217]  J M Sorace,et al.  Structure of the gene for human von Willebrand factor. , 1989, The Journal of biological chemistry.

[218]  J. Moake,et al.  Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. , 1989, The American journal of medicine.

[219]  J. Moake,et al.  Cryosupernatant regulates accumulation of unusually large vWF multimers from endothelial cells. , 1989, The American journal of physiology.

[220]  R. Bellevue,et al.  Thrombotic Thrombocytopenic Purpura in Patients with the Acquired Immunodeficiency Syndrome (AIDS)-Related Complex: A Report of Two Cases , 1988 .

[221]  S. Karpatkin,et al.  Thrombotic thrombocytopenic purpura associated with human immunodeficiency virus type 1 (HIV-1) infection. , 1988, Annals of internal medicine.

[222]  W. Proesmans,et al.  The hemolytic uremic syndrome of childhood and its variants. , 1987, Seminars in hematology.

[223]  J. Moake,et al.  Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. , 1986, The Journal of clinical investigation.

[224]  R. Goldberg,et al.  Treatment of cancer-associated hemolytic uremic syndrome with staphylococcal protein A immunoperfusion. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[225]  J. Moake,et al.  Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathioprine , 1985, American journal of hematology.

[226]  Y. Asada,et al.  Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. , 1985, Thrombosis research.

[227]  K. Atkinson,et al.  Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes , 1983, British journal of haematology.

[228]  D. Deykin,et al.  Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. , 1982, The New England journal of medicine.

[229]  J. Khandekar,et al.  Mitomycin-induced hemolytic uremic syndrome: case presentation and review of literature. , 1982, Cancer treatment reports.

[230]  L. Gutterman,et al.  Treatment of thrombotic thrombocytopenic purpura with vincristine. , 1982, JAMA.

[231]  J. Byrnes,et al.  Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. , 1981, JAMA.

[232]  G. Hutchins,et al.  The heart and cardiac conduction system in thrombotic thrombocytopenic purpura. A clinicopathologic study of 17 autopsied patients. , 1979, Annals of internal medicine.

[233]  P. Blatt,et al.  Thrombotic thrombocytopenic purpura: a pathology review. , 1979, JAMA.

[234]  J. Byrnes,et al.  Presence of a platelet aggregating factor in the plasma of patients with thrombotic thrombocytopenic purpura (TTP) and its inhibition by normal plasma. , 1979, Blood.

[235]  A. Goodman,et al.  Gingival biopsy in thrombotic thrombocytopenic purpura. , 1978, Annals of internal medicine.

[236]  J. Upshaw.  Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. , 1978, The New England journal of medicine.

[237]  J. Byrnes,et al.  Treatment of thrombotic thrombocytopenic purpura with plasma. , 1977, The New England journal of medicine.

[238]  J. Denburg,et al.  Thrombotic thrombocytopenic purpura: a syndrome of intravascular platelet consumption. , 1976, Canadian Medical Association journal.

[239]  L. Zacharski,et al.  Thrombotic thrombocytopenic purpura in a previously splenectomized patient. , 1976, The American journal of medicine.

[240]  T. N. James,et al.  Pathology of the cardiac conduction system in thrombotic thrombocytopenic purpura. , 1966, Annals of internal medicine.

[241]  J. Ultmann,et al.  THROMBOTIC THROMBOCYTOPENIC PURPURA: REPORT OF 16 CASES AND REVIEW OF THE LITERATURE , 1966 .

[242]  I. Schulman,et al.  Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. , 1960, Blood.

[243]  B. Kagan,et al.  Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions. , 1959, Annals of internal medicine.

[244]  J. Craig,et al.  The nature of the hyaline thrombi in thrombotic thrombocytopenic purpura. , 1957, The American journal of pathology.

[245]  A. Steck,et al.  [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia]. , 1955, Schweizerische medizinische Wochenschrift.

[246]  E. Moschcowitz.  An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries; an undescribed disease. , 1952, The American journal of medicine.

[247]  D. Riesman.  HEMORRHAGES IN THE COURSE OF BRIGHT'S DISEASE, WITH ESPECIAL REFERENCE TO THE OCOURBENOE OF A HEMORRHAGIC DIATHESIS OF NEPHRITIC ORIGIN , 1907 .

[248]  C. Legendre,et al.  New insights into postrenal transplant hemolytic uremic syndrome , 2011, Nature Reviews Nephrology.

[249]  J. Poisson,et al.  Is it quinine TTP/HUS or quinine TMA? ADAMTS13 levels and implications for therapy , 2009, Journal of clinical apheresis.

[250]  T. Nakagaki,et al.  Quantitative Western blot analysis of plasma ADAMTS13 antigen in patients with Upshaw-Schulman syndrome. , 2007, Thrombosis research.

[251]  C. Ball,et al.  Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. , 2007, Haematologica.

[252]  J. Fehr,et al.  Novel, semi-automated, 60-min-assay to determine von Willebrand factor cleaving activity of ADAMTS-13. , 2006, Thrombosis research.

[253]  A. Veyradier,et al.  Assays of ADAMTS-13 activity. , 2004, Seminars in hematology.

[254]  B. Lämmle,et al.  Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. , 2004, Haematologica.

[255]  J. Moake,et al.  Recent advances in thrombotic thrombocytopenic purpura. , 2004, Hematology. American Society of Hematology. Education Program.

[256]  R. Sarode,et al.  Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accident , 2004, Journal of clinical apheresis.

[257]  J. Moake.  Thrombotic microangiopathies. , 2002, The New England journal of medicine.

[258]  G. Rock,et al.  Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. , 2001, Clinical laboratory.

[259]  C. Nzerue,et al.  Cocaine-induced acute renal failure, hemolysis, and thrombocytopenia mimicking thrombotic thrombocytopenic purpura. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[260]  S. Fan,et al.  Tacrolimus (FK 506) induced thrombotic thrombocytopenic purpura after ABO mismatched second liver transplantation: salvage with plasmapheresis and prostacyclin. , 2000, Haematologica.

[261]  B. Lämmle,et al.  Recovery and Half-Life of von Willebrand Factor-Cleaving Protease after Plasma Therapy in Patients with Thrombotic Thrombocytopenic Purpura , 1999, Thrombosis and Haemostasis.

[262]  G. D. del Zoppo.  Antiplatelet therapy in thrombotic thrombocytopenic purpura. , 1987, Seminars in hematology.

[263]  J. Byrnes,et al.  Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura. , 1985, Blood.

[264]  H. Lior,et al.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. , 1985, The Journal of infectious diseases.

[265]  D. Goldfinger,et al.  Ineffectiveness of aspirin and dipyridamole in the treatment of thrombotic thrombocytopenic purpura. , 1982, Annals of internal medicine.

[266]  J. Moake,et al.  Effects of antiplatelet agents on platelets exposed to shear stress. , 1980, Transactions - American Society for Artificial Internal Organs.

[267]  P. Neame.  Immunologic and Other Factors in Thrombotic Thrombocytopenic Purpura (TTP) , 1980, Seminars in thrombosis and hemostasis.

[268]  R. Hartmann,et al.  Thrombotic thrombocytopenic purpura; two patients with remission associated with the use of large amounts of steroids. , 1959, A.M.A. archives of internal medicine.

[269]  E. Moschcowitz.  Hyaline thrombosis of the terminal arterioles and capillaries : a hitherto undescribed disease , 1924 .